Pivotal studies of obinutuzumab- vs rituximab-based treatment regimens in B-NHL
| B-NHL . | Trial . | Regimens . | Efficacy . | Toxicity . | |||||
|---|---|---|---|---|---|---|---|---|---|
| O based . | R based . | Parameter . | O . | R . | Parameter . | O . | R . | ||
| CLL | CLL115 | O-chlorambucil | R-chlorambucil | 5-y OS, % | 66 | 57 | All grade 3-5 AEs, % | 72 | 60 |
| CLL136 | O-venetoclax | R-venetoclax | 3-y PFS, % | 88 | 81 | All grade 3-4 AEs, % Grade 3-4 infections, % | 80 13 | 70 11 | |
| FL | GALLIUM4 | O-Benda/O-CVP/O-CHOP | R-Benda/R-CVP/R-CHOP | 7-y PFS, % | 63 | 56 | All grade 3-5 AEs, % Grade 3-5 infections, % CHOP, induction Benda, maintenance | 75 64 17 | 68 51 13 |
| MCL | LYMA-1011 and LYMA2 ∗ | O-DHAP -> ASCT -> O maintenance | R-DHAP -> ASCT -> R maintenance | 5-y OS, % | 86 | 71 | Grade 3-5 AEs, % Grade 3-5 infections, % | 96 56 | N/A N/A |
| DLBCL | GOYA7 | O-CHOP | R-CHOP | 3-y PFS, % | 70 | 67 | All grade 3-5 AEs, % Grade 3-5 infections, % | 74 17 | 65 16 |
| B-NHL . | Trial . | Regimens . | Efficacy . | Toxicity . | |||||
|---|---|---|---|---|---|---|---|---|---|
| O based . | R based . | Parameter . | O . | R . | Parameter . | O . | R . | ||
| CLL | CLL115 | O-chlorambucil | R-chlorambucil | 5-y OS, % | 66 | 57 | All grade 3-5 AEs, % | 72 | 60 |
| CLL136 | O-venetoclax | R-venetoclax | 3-y PFS, % | 88 | 81 | All grade 3-4 AEs, % Grade 3-4 infections, % | 80 13 | 70 11 | |
| FL | GALLIUM4 | O-Benda/O-CVP/O-CHOP | R-Benda/R-CVP/R-CHOP | 7-y PFS, % | 63 | 56 | All grade 3-5 AEs, % Grade 3-5 infections, % CHOP, induction Benda, maintenance | 75 64 17 | 68 51 13 |
| MCL | LYMA-1011 and LYMA2 ∗ | O-DHAP -> ASCT -> O maintenance | R-DHAP -> ASCT -> R maintenance | 5-y OS, % | 86 | 71 | Grade 3-5 AEs, % Grade 3-5 infections, % | 96 56 | N/A N/A |
| DLBCL | GOYA7 | O-CHOP | R-CHOP | 3-y PFS, % | 70 | 67 | All grade 3-5 AEs, % Grade 3-5 infections, % | 74 17 | 65 16 |
AE, adverse event; Benda, bendamustine; B-NHL, B-cell non-Hodgkin lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CLL, chronic lymphocytic leukemia; CVP, cyclophosphamide, vincristine, prednisone; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; N/A, not applicable.
Not a comparison via a randomized phase 3 trial; indirect comparison assessment via propensity score matching. All other trials listed are randomized phase 3 studies.